Trade Cellectar Biosciences, Inc. - CLRB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.35 |
| Open | 0.32 |
| 1-Year Change | -87.74% |
| Day's Range | 0.31 - 0.32 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 0.31 | -0.01 | -3.13% | 0.32 | 0.32 | 0.31 |
| Mar 27, 2025 | 0.35 | 0.00 | 0.00% | 0.35 | 0.35 | 0.35 |
| Mar 25, 2025 | 0.36 | 0.00 | 0.00% | 0.36 | 0.36 | 0.36 |
| Mar 24, 2025 | 0.37 | 0.00 | 0.00% | 0.37 | 0.37 | 0.37 |
| Mar 18, 2025 | 0.34 | 0.00 | 0.00% | 0.34 | 0.34 | 0.34 |
| Mar 13, 2025 | 0.29 | 0.00 | 0.00% | 0.29 | 0.29 | 0.29 |
| Feb 25, 2025 | 0.27 | 0.00 | 0.00% | 0.27 | 0.27 | 0.27 |
| Jan 7, 2025 | 0.32 | -0.01 | -3.03% | 0.33 | 0.33 | 0.32 |
| Dec 31, 2024 | 0.27 | 0.00 | 0.00% | 0.27 | 0.27 | 0.27 |
| Dec 30, 2024 | 0.28 | 0.00 | 0.00% | 0.28 | 0.28 | 0.28 |
| Dec 27, 2024 | 0.29 | 0.00 | 0.00% | 0.29 | 0.29 | 0.29 |
| Dec 17, 2024 | 0.24 | 0.00 | 0.00% | 0.24 | 0.24 | 0.24 |
| Dec 11, 2024 | 0.34 | -0.05 | -12.82% | 0.39 | 0.39 | 0.34 |
| Dec 10, 2024 | 1.25 | -0.08 | -6.02% | 1.33 | 1.34 | 1.24 |
| Dec 9, 2024 | 1.32 | -0.02 | -1.49% | 1.34 | 1.36 | 1.31 |
| Dec 6, 2024 | 1.36 | 0.01 | 0.74% | 1.35 | 1.38 | 1.34 |
| Dec 5, 2024 | 1.34 | -0.11 | -7.59% | 1.45 | 1.45 | 1.34 |
| Dec 4, 2024 | 1.44 | -0.02 | -1.37% | 1.46 | 1.46 | 1.41 |
| Dec 3, 2024 | 1.44 | -0.07 | -4.64% | 1.51 | 1.51 | 1.40 |
| Dec 2, 2024 | 1.49 | -0.04 | -2.61% | 1.53 | 1.53 | 1.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cellectar Biosciences, Inc. Company profile
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.
Equity composition
Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.
| Industry: | Pharmaceuticals (NEC) |
100 Campus Drive
FLORHAM PARK
NEW JERSEY 07932
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com